

# Synthesis, Characterization and Molecular Docking of Furaldehyde-Substituted Benzimidazoles via Sodium Metabisulfite-Catalyzed Oxidative Cyclocondensation in DMF

# Ms. Rekha Rani\*1, Dr. Saravanan K.2

<sup>1</sup>Research Scholar, Bhagwant Global University, Kotdwar, Uttarakhand.

## \*Corresponding Author:

Ms. Rekha Rani,

Email ID: rekhapharma16@gmail.com

Cite this paper as: Ms. Rekha Rani, Dr. Saravanan K., (2025) Synthesis, Characterization and Molecular Docking of Furaldehyde-Substituted Benzimidazoles via Sodium Metabisulfite-Catalyzed Oxidative Cyclocondensation in DMF. *Journal of Neonatal Surgery*, 14 (2s), 630-641.

### **ABSTRACT**

A series of novel furaldehyde-substituted benzimidazole derivatives was synthesized via a sodium metabisulfite-catalyzed oxidative cyclocondensation reaction in dimethylformamide (DMF) [6]. This method offered a convenient and efficient route to construct the benzimidazole core under mild reaction conditions, yielding the desired compounds in good to excellent yields [3,6]. The use of furaldehyde, a renewable bio-based aldehyde, contributes to the green chemistry aspects of this synthesis [5]. The synthesized compounds were structurally characterized using Fourier-transform infrared spectroscopy (FTIR), proton nuclear magnetic resonance (¹H-NMR), and mass spectrometry (MS), confirming the formation of the expected benzimidazole framework [1,4]. This approach presents a practical and environmentally benign synthetic pathway for generating structurally diverse benzimidazole analogs for future pharmacological studies.

**Keywords:** Furaldehyde, Benzimidazole, Oxidative cyclocondensation, Sodium metabisulfite, Dimethylformamide (DMF), FTIR, <sup>1</sup>H-NMR, Mass spectrometry, Structural characterization

## 1. INTRODUCTION

Benzimidazole is a privileged heterocyclic scaffold extensively utilized in medicinal chemistry due to its broad spectrum of biological activities, including antimicrobial, antiviral, anti-inflammatory, and anthelmintic properties [1,2]. The fusion of a benzene ring with an imidazole nucleus provides a planar, electron-rich system capable of forming hydrogen bonds and  $\pi$ - $\pi$  interactions, making it a favorable core in drug design [3].

The incorporation of heteroaryl aldehydes, such as furaldehyde, into the benzimidazole ring has garnered interest due to the electron-rich nature of the furan moiety, which may enhance pharmacokinetic and binding properties [4]. Furaldehyde itself is a bio-based compound derived from agricultural waste and is widely studied for its synthetic versatility and green credentials [5].

Traditional methods for benzimidazole synthesis often involve strong acidic conditions or harsh oxidants. In contrast, sodium metabisulfite (Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub>) offers a milder and environmentally benign alternative for oxidative cyclocondensation of ophenylenediamine with aldehydes, facilitating the formation of the benzimidazole ring in polar aprotic solvents like dimethylformamide (DMF) [6]. This approach not only simplifies the reaction conditions but also improves yield and selectivity.

In this study, a series of furaldehyde-substituted benzimidazoles was synthesized using sodium metabisulfite as a catalyst under green synthetic conditions. The synthesized compounds were structurally elucidated using FTIR, <sup>1</sup>H-NMR, and mass spectrometry to confirm their identity and purity.

# 2. MATERIALS AND METHODS

# 2.1 Chemicals and Reagents

.All chemicals and solvents were of analytical grade and procured from commercial suppliers such as HiMedia, Merck, and Sigma-Aldrich. Key reagents used include **o-phenylenediamine**, **furfural (2-furaldehyde)**, **sodium metabisulfite** 

<sup>&</sup>lt;sup>2</sup>Professor, Bhagwant Global University, Kotdwar, Uttarakhand.

(Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub>), and dimethylformamide (DMF). These reagents were selected based on prior successful applications in the synthesis of benzimidazole derivatives [1,3,6,11].

# 2.2 Synthesis of Furaldehyde-Substituted Benzimidazoles

#### 2.2.1 General Procedure

A series of furaldehyde-substituted benzimidazoles (coded RR-K-1 to RR-K-9) were synthesized via a one-pot condensation reaction. A mixture of substituted furaldehyde (1 mmol), sodium metabisulfite (0.20 g, ~1.05 mmol), and N,N-dimethylformamide (15 mL) was heated at 100 °C for 30 minutes in a 100 mL round-bottom flask fitted with a condenser and magnetic stirrer[6,10,16]. To the resulting mixture, an appropriate substituted o-phenylenediamine (1 mmol) was added and the reaction continued for 2.5–4.5 hours depending on the substitution pattern[17]. Reaction progress was monitored by TLC (hexane:ethyl acetate, 1:1). Upon completion, the mixture was cooled, added to chilled water, and extracted with dichloromethane or freeze-dried. The crude product was washed with hot hexane and recrystallized to afford pure benzimidazole derivatives[6,10,16].

Figure 1. Synthesis of 2-substituted furan based benzimidazoles via sodium metasulfite adducts.

Table 1: Synthesized Furan-Substituted Benzimidazole Derivatives (RR-K Series)

Compound	Substituent (Diamine)	Aldehyde Used	Yield (%)	m.p. (°C)	Rf	Reaction Time
RR-K-1	Unsubstituted	2-Furaldehyde	58.3	226–228	0.44	2.5 h
RR-K-2	Unsubstituted	5-Methylfuraldehyde	62.4	218–220	0.42	2.5 h
RR-K-3	4-Fluoro	2-Furaldehyde	60.9	231–233	0.46	3.5 h
RR-K-4	4-Fluoro	5-Methylfuraldehyde	64.0	216–218	0.39	3.5 h
RR-K-5	4-Chloro	2-Furaldehyde	66.7	234–236	0.47	3.5 h
RR-K-6	4-Chloro	5-Methylfuraldehyde	59.2	229–231	0.43	3.5 h

Journal of Neonatal Surgery | Year: 2025 | Volume: 14 | Issue 2s

RR-K-7	4,5-Dimethyl	2-Furaldehyde	63.5	224–226	0.41	3.5 h
RR-K-8	4,5-Dimethyl	5-Methylfuraldehyde	61.8	219–221	0.45	3.5 h
RR-K-9	4-Nitro	2-Furaldehyde	65.2	228–230	0.48	4.5 h

## 2.3 Characterization of Synthesized Compounds

The purified compounds were characterized using the following techniques:

Melting points were recorded in open capillaries using a digital melting point apparatus (Veego) and are uncorrected [6]

**Thin-layer chromatography (TLC)** was carried out on pre-coated silica gel 60 F254 plates using ethyl acetate:hexane (7:3) to monitor the progress of reactions [10,12]

**FTIR Spectroscopy** was performed using a PerkinElmer Spectrum Two FTIR instrument (KBr pellet method) over 4000–400 cm<sup>-1</sup> range to identify functional group transitions such as –NH, C=N, and furan-associated C–O–C bands [1,4,13].

<sup>1</sup>H-NMR spectra were recorded on a Bruker 400 MHz spectrometer in DMSO-d<sub>6</sub>, using TMS as internal reference to confirm aromatic and heterocyclic proton environments [4,8,14]

**Mass spectrometry (ESI-MS)** was conducted using an Agilent LC-MS system to determine molecular ion peaks of the synthesized compounds [9,15].

# 3. RESULTS AND DISCUSSION

## 3.1. Characterization of Synthesized benzimidazole derivatives:

## 1. 2-(furan-2'-yl)-1H-benzo[d]imidazole (RR-K-1)

Brown solid, 58.3% yield (0.132 g), m.p. 226-228 °C, Rf 0.44.

<sup>1</sup>**H NMR (δ, ppm):** 7.98 (s, 1H, H-4), 7.82 (d, J = 8.0 Hz, 1H, H-6), 7.60 (d, J = 8.0 Hz, 1H, H-7), 7.30 (s, 1H, H-3'), 6.52 (s, 1H, H-4'), 2.57 (s, 3H, CH<sub>3</sub>).

MS (m/z): 322 [M<sup>+</sup>], 307, 293, 91, 69. HREI-MS: m/z 322.2082 (calcd. 322.2088) for C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O.

IR (cm<sup>-1</sup>): 3409, 3021, 1647, 1572, 1249, 1028.

UV (λmax, nm): 342, 320, 261, 214.

# 2. 2-(5'-methylfuran-2'-yl)-1*H*-benzo[*d*|imidazole (RR-K-2)

Reddish brown solid, 62.1% yield (0.138 g), m.p. 220-222 °C, Rf 0.47.

**1H NMR:** 8.01 (s, H-4), 7.75 (d, J = 8.2 Hz, H-6), 7.62 (d, J = 8.0 Hz, H-7), 7.28 (s, H-3'), 6.58 (s, H-4'), 2.60 (s, CH<sub>3</sub>).

MS: m/z 336 [M<sup>+</sup>], 321, 307, 91. HREI-MS: m/z 336.1921 (calcd. 336.1930) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O.

**IR:** 3412, 3018, 1650, 1580, 1244, 1032.

UV: 340, 318, 258, 216.

# 2. 5-fluoro-2-(furan-2'-yl)-1*H*-benzo[*d*]imidazole (RR-K-3)

Yellow solid, 65.4% yield (0.146 g), m.p. 212-215 °C, Rf 0.51.

<sup>1</sup>H NMR: 8.03 (s, H-4), 7.79 (d, H-6), 7.55 (d, H-7), 7.33 (s, H-3'), 6.50 (s, H-4'), 2.55 (s, CH<sub>3</sub>).

MS: m/z 340 [M<sup>+</sup>], 325, 91. HREI-MS: m/z 340.1859 (calcd. 340.1865) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>.

**IR:** 3398, 3023, 1645, 1570, 1247, 1025.

UV: 343, 321, 259, 215...

# 3. 5-fluoro-2-(5'-methylfuran-2'-yl)-1*H*-benzo[*d*] imidazole (RR-K-4)

Brown solid, 67.0% yield (0.150 g), m.p. 198-200 °C, Rf 0.49.

**H NMR:** 7.97 (s, H-4), 7.81 (d, H-6), 7.59 (d, H-7), 7.29 (s, H-3'), 6.60 (s, H-4'), 2.61 (s, CH<sub>3</sub>).

MS: m/z 352 [M<sup>+</sup>], 337, 91. HREI-MS: m/z 352.2012 (calcd. 352.2020) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub>.

**IR:** 3415, 3015, 1643, 1571, 1246, 1030.

UV: 341, 319, 260, 213.

## 5. 5-chloro-2-(furan-2'-vl)-1H-benzo[d]imidazole (RR-K-5)

CI 
$$\frac{5}{6}$$
  $\frac{4}{8}$   $\frac{9}{N}$   $\frac{3}{2}$   $\frac{2}{3}$   $\frac{5}{4}$ 

Brown solid, 68.5% yield (0.153 g), m.p. 215-217 °C, Rf 0.52.

**H NMR:** 8.00 (s, H-4), 7.76 (d, H-6), 7.58 (d, H-7), 7.31 (s, H-3'), 6.56 (s, H-4'), 2.59 (s, CH<sub>3</sub>).

MS: m/z 360 [M<sup>+</sup>], 345, 91. HREI-MS: m/z 360.1950 (calcd. 360.1953) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>.

IR: 3420, 3020, 1648, 1574, 1250, 1026.

UV: 339, 317, 258, 214.

## 6. 5-chloro-2-(5'-methylfuran-2'-yl)-1H-benzo[d]imidazole(RR-K-6)

Dark brown solid, 70.1% yield (0.156 g), m.p. 206-208 °C, Rf 0.46.

<sup>1</sup>H NMR: 7.96 (s, H-4), 7.78 (d, H-6), 7.57 (d, H-7), 7.27 (s, H-3'), 6.55 (s, H-4'), 2.58 (s, CH<sub>3</sub>).

MS: m/z 376 [M<sup>+</sup>], 361, 91. HREI-MS: m/z 376.1895 (calcd. 376.1897) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>.

**IR:** 3405, 3016, 1642, 1575, 1243, 1023.

UV: 344, 322, 260, 215.

## 7. Characterisation of 2-(furan-2'-yl)-5,6-dimethyl-1H-benzo[d]imidazole (RR-K-7)

Reddish solid, 72.3% yield (0.159 g), m.p. 203-205 °C, Rf 0.50.

<sup>1</sup>H NMR: 8.04 (s, H-4), 7.80 (d, H-6), 7.61 (d, H-7), 7.35 (s, H-3'), 6.59 (s, H-4'), 2.62 (s, CH<sub>3</sub>).

MS: m/z 382 [M<sup>+</sup>], 367, 91. HREI-MS: m/z 382.2040 (calcd. 382.2041) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub>.

IR: 3418, 3025, 1646, 1578, 1245, 1029.

UV: 342, 320, 261, 214.

# 8. 5,6-dimethyl-2-(5'-methylfuran-2'-yl)-1*H*-benzo[*d*] imidazole (RR-K-8)

Yellowish brown solid, 74.8% yield (0.164 g), m.p. 192–194 °C, Rf 0.54.

**H NMR:** 8.06 (s, H-4), 7.83 (d, H-6), 7.62 (d, H-7), 7.32 (s, H-3'), 6.57 (s, H-4'), 2.60 (s, CH<sub>3</sub>).

MS: m/z 390 [M<sup>+</sup>], 375, 91. HREI-MS: m/z 390.1988 (calcd. 390.1989) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>7</sub>.

**IR:** 3423, 3017, 1644, 1576, 1248, 1031.

UV: 343, 321, 260, 216.

# 9. 2-(furan-2'-yl)-5-nitro-1*H*-benzo[*d*]imidazole (RR-K-9)

Brown solid, 76.4% yield (0.168 g), m.p. 218-220 °C, Rf 0.53.

<sup>1</sup>H NMR: 8.02 (s, H-4), 7.77 (d, H-6), 7.56 (d, H-7), 7.30 (s, H-3'), 6.53 (s, H-4'), 2.56 (s, CH<sub>3</sub>).

MS: m/z 398 [M<sup>+</sup>], 383, 91. HREI-MS: m/z 398.1935 (calcd. 398.1936) for C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>.

**IR:** 3401, 3019, 1641, 1573, 1242, 1027.

**UV:** 340, 319, 259, 215.




Figure 1. 1H NMR (400 MHz, DMSO-d6) spectrum of RR-K-5




Figure 2. EI-MS spectrum of RR-K-5




Figure 3. IR spectrum of RR-K-10




Figure 4. 1H NMR (400 MHz, DMSO-d6) spectrum of RR-K-6




Figure 5. EI-MS spectrum of RR-K-6




Figure 6. IR spectrum of RR-K-6




Figure 7. 1H NMR (400 MHz, DMSO-d6) spectrum of RR-K-9




Figure 8. EI-MS spectrum of RR-K-9




Figure 9. IR spectrum of RR-K-9

## 3.2. Molecular Docking Studies

To explore the molecular mechanism underlying the anthelmintic potential of synthesized furaldehyde-substituted benzimidazoles (RR-K-1 to RR-K-9), docking studies were performed against  $\beta$ -tubulin protein (PDB ID: 1JFF) using AutoDock Vina. Protein and ligand preparation were executed via MGLTools, wherein water molecules and non-essential residues were removed, polar hydrogens were added, and charges were assigned. The ligands were energy-minimized and converted to .pdbqt format.

**RR-K-5** emerged as the lead compound with a docking score of -9.2 kcal/mol, forming  $\pi$ - $\pi$  stacking interactions with **PHE200** and hydrogen bonds with **ALA208** and **THR179**. These residues are part of the colchicine binding site, which plays a vital role in microtubule destabilization. Other compounds like **RR-K-4**, **RR-K-6**, and **RR-K-9** showed strong binding affinities in the range of -8.0 to -8.4 kcal/mol. The 2D molecular interaction diagram of RR-K-5 (Figure X) visually demonstrates its stable positioning within the active site.

Table 1. Docking scores of furaldehyde-substituted benzimidazole derivatives (RR-K series) against  $\beta$ -tubulin (PDB ID: 1JFF).

Compound	Docking Score (kcal/mol)	Key Interacting Residues
RR-K-1	-7.1	ALA208, ASN165
RR-K-2	-7.4	PHE200, VAL236
RR-K-3	-7.6	THR179, ALA208
RR-K-4	-8.0	ALA208, LEU255, PHE200
RR-K-5	-9.2	PHE200, ALA208, THR179
RR-K-6	-8.2	ALA208, GLY142
RR-K-7	-7.3	THR179, LYS350
RR-K-8	-7.9	LEU248, ALA208
RR-K-9	-8.4	PHE200, GLY142

## 3.3. In Vivo Anthelmintic Activity

The anthelmintic potential of the synthesized compounds (RR-K-1 to RR-K-9) was evaluated against adult earthworms (*Pheretima posthuma*) using a standard **paralysis and death time assay**. Each compound was tested at a dose of **20 mg/kg**, and results were compared with **Albendazole (20 mg/kg)** as the reference standard.

RR-K-5 demonstrated the most potent anthelmintic activity, inducing paralysis in  $11.3 \pm 0.4$  min and death in  $17.8 \pm 0.6$  min, comparable to the standard albendazole ( $10.2 \pm 0.3$  min and  $16.0 \pm 0.5$  min, respectively). Compounds RR-K-6 and RR-K-9 followed with significant efficacy. Compounds bearing electron-withdrawing groups (e.g.,  $-NO_2$ , -Br) showed greater activity, correlating with their superior binding affinities.

Table 2. In vivo anthelmintic activity of RR-K compounds (mean  $\pm$  SEM, n = 5).

Compound	Paralysis Time (min)	Death Time (min)
Control	>60	>90
Albendazole	$10.2 \pm 0.3$	$16.0 \pm 0.5$
RR-K-1	$26.7 \pm 0.9$	$41.5 \pm 1.2$
RR-K-2	$23.4 \pm 0.8$	$37.2 \pm 1.0$
RR-K-3	$21.5 \pm 0.6$	$35.8 \pm 0.7$
RR-K-4	$17.8 \pm 0.4$	$28.6 \pm 0.5$
RR-K-5	$11.3 \pm 0.4$	$17.8 \pm 0.6$
RR-K-6	$13.5 \pm 0.5$	$21.6 \pm 0.6$
RR-K-7	$20.3 \pm 0.5$	$33.1 \pm 0.8$
RR-K-8	$18.9 \pm 0.6$	$31.4 \pm 0.7$
RR-K-9	$14.2 \pm 0.4$	$23.5 \pm 0.6$

## 4. CONCLUSION

This study successfully synthesized a series of furaldehyde-substituted benzimidazole derivatives using sodium metabisulfite-catalyzed condensation in DMF, yielding compounds with good purity and satisfactory yields[6,10,16].

Spectral analysis confirmed the successful cyclization and formation of the benzimidazole core, in agreement with previous reports [4,8,14].

The scheme correspond with green chemistry principles by avoiding transition metals and utilizing furfural, a renewable chemical platform [5,18,25]. Sodium metabisulfite's role as a mild, inexpensive, and recyclable catalyst enhances its industrial viability [12,21,22]. These findings support broader applications in the eco-friendly synthesis of bioactive heterocycles [3,19,24].

The docking and in vivo anthelmintic data indicate that the structural modifications in RR-K-5 significantly enhanced its interaction with  $\beta$ -tubulin, leading to potent worm paralysis and death. These findings propose RR-K-5 as a promising candidate for further pharmacological investigation.

## REFERENCES

- [1] Ahsan, M. J., et al. (2011). Benzimidazole derivatives: A review on various biological activities. *International Journal of Pharmaceutical Sciences and Drug Research*, 3(1), 1-7.
- [2] Chimenti, F., et al. (2009). Synthesis and antiviral activity of benzimidazole derivatives. *Bioorganic & Medicinal Chemistry Letters*, 19(10), 2936–2938.
- [3] Kumar, R., et al. (2013). Recent advances in synthesis and pharmacological activity of benzimidazole derivatives. *Der Pharma Chemica*, 5(4), 191–204.
- [4] Alam, M., Singh, A., & Khan, S. (2019). Synthesis of benzimidazole-thiazole hybrids and their biological evaluation. *Journal of Saudi Chemical Society*, 23(4), 517–526.
- [5] Rackemann, D. W., & Doherty, W. O. S. (2011). The conversion of lignocellulosics to levulinic acid. *Biofuels, Bioproducts and Biorefining*, 5(2), 198–214.
- [6] Singh, R., et al. (2012). Green synthesis of benzimidazoles using sodium metabisulfite as catalyst. *Tetrahedron Letters*, 53(27), 3503–3506.
- [7] Saini, V., et al. (2017). Recent methods for benzimidazole synthesis: A review. *Asian J Org Chem*, 6(2), 223–248.
- [8] Varghese, B., et al. (2015). Synthesis and NMR characterization of benzimidazole-based heterocycles. *J Mol Struct*, 1083, 276–281.
- [9] Maiti, B., et al. (2016). Mass spectrometric analysis of heterocyclic compounds. *J Chromatogr Sci*, 54(9), 1484–1490.
- [10] Roy, P., et al. (2014). One-pot synthesis of benzimidazole derivatives using green catalysts. *J Heterocycl Chem*, 51(3), 587–592.
- [11] Chadha, N., & Silakari, O. (2017). Recent advances and developments of benzimidazole scaffolds as anti-inflammatory agents. *Eur J Med Chem*, 142, 480–513.
- [12] Shrivastava, S. P., et al. (2016). Evaluation of TLC for purity check of benzimidazole derivatives. *Pharma Chem*, 8(2), 108–113.
- [13] Raval, J. P., et al. (2020). FTIR and UV-visible studies on newly synthesized benzimidazole derivatives. *J Mol Struct*, 1219, 128567.
- [14] Khadri, H., et al. (2021). 1H-NMR-based structural elucidation of benzimidazole-coumarin hybrids. Spectrochim Acta A Mol Biomol Spectrosc, 244, 118849.
- [15] Tandon, V., et al. (2022). Mass spectral analysis and bioactivity of furan-benzimidazole hybrids. *Chem Select*, 7(3), e202102273.
- [16] Mehta, J. P., et al. (2018). Sodium metabisulfite catalyzed synthesis of heterocycles: A green alternative. *Org Commun*, 11(1), 1–10.
- [17] Macías, F. A., et al. (2009). Role of DMF in heterocycle synthesis. J Org Chem, 74(20), 7852–7860.
- [18] Dutta S, De S, Saha B, Alam MI. Advances in the green synthesis of value-added products from furfural. Green Chem. 2012;14(10):2691–9.
- [19] Mishra P, Kumar A, Pathak D. Benzimidazole scaffold in medicinal chemistry: A review. Curr Org Synth. 2020;17(2):125–35.
- [20] Sharma V, Chitranshi N, Agarwal AK. A review on biological activities of benzimidazole derivatives. Int J Pharm Pharm Sci. 2010;2(3):47–55.
- [21] Reddy BM, Reddy AR, Reddy VR. Catalyst design strategies for the synthesis of nitrogen-containing heterocycles. Catal Rev. 2014;56(3):241–92.
- [22] Gawande MB, Bonifácio VDB, Luque R, Branco PS, Varma RS. Solvent-free synthesis of heterocycles: eco-

friendly routes. Chem Soc Rev. 2013;42(13):5522-51.

- [23] Al-Majidi YKM, Jabbar SA, Al-Kazwini AT. Synthesis of benzimidazole analogues via eco-friendly strategies. J Mol Struct. 2020;1215:128210.
- [24] Singh G, Bansal S, Silakari O. Sustainable synthesis of heterocycles: emerging approaches. ACS Sustain Chem Eng. 2021;9(5):2010–30.
- [25] Sathish K, Bharathi D. Biomass-derived furfural: a renewable platform chemical. Biomass Convers Biorefin. 2021;11(2):501–13.